This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of CBD administered as ZYN002, a transdermal gel, for the treatment of children and adolescent patients with FXS.
Age & Gender
- 3 years ~ 18 years
- Male, Female, Gender Inclusive
Study Interest
- Child and Teen Health
- Developmental
- Parents of Children
Status: Not currently enrolling